These receptor tyrosine kinases are known to play important roles in the pathogenesis of RCC (6, 7) . In phase III trials, this agent was shown to significantly improve the median progression-free survival (PFS), and yield a higher response rate (RR), and afford a better quality of life over interferon-alfa (8) . However, these studies were performed mainly in Western populations. Therefore, further studies about the efficacy and safety profiles are needed for involving Asian RCC treated with sunitinib.
We retrospectively performed this descriptive study to assess the efficacy and toxicity profiles of sunitinib to determine whether there is a difference in Korean patients with metastatic RCC compared to Western patients.
M a t e r i a l s a n d M e t h o d s

Patients
The medical records of RCC patients with recurrent or metastatic disease who had received sunitinib treatment at the Yonsei University Health System (YUHS) between January 2005 and December 2008 were retrospectively reviewed. The inclusion criteria were as follows; Asian ethnicity, metastatic RCC treated with sunitinib, and patients with available medical data for evaluating efficacy and toxicity. Clinicopathologic factors such as age, gender, tumor histology, Eastern Cooperative Oncology Group performance status (ECOG PS), the number of prior treatments, sites of metastasis, laboratory findings, and patient survival were collected retrospectively and analyzed. We also assessed the Memorial Sloan-Kettering Cancer Center (MSKCC) risk scoring system according to a previous study (9) .
Sunitinib treatment
Sunitinib was prescribed as a part of clinical or non-clinical trials with 2 different schedules: group 1, 50 mg orally once daily for 4 weeks followed by a 2 week rest period (50 mg 4 weeks on -2 weeks off schedule); and group 2, 37.5 mg daily continuous dosing. For the evaluation of the response, Response Evaluation Criteria In Solid Tumors (RECIST) was applied (10) . Regular physical examinations and computed tomography or magnetic resonance imaging were performed for treatment outcome every 6 8 weeks. Toxicity was evaluated during the sunitinib treatment according to the National Cancer Institute common toxicity criteria (version 3.0). The median PFS was 7.2 months (95% confidence interval [CI], 4.7 9.7 months, Fig. 1 ), and the median OS was 22.8 months (95% CI, 18.7 26.9 months, Fig. 2 ). The 1-year PFS rate and 1-year OS rate were 36.8% (95% CI, 26.1 48.7%) and 61.8% (95% CI, 50.0 72.6%), respectively. Of the 786 evaluable patients, objective RR (including complete and partial responses) was 27.6% (95% CI, 18.0 39.1%) and the disease control rate (including complete response, partial response, and stable disease) was 84.2% (95% CI, 74.0 91.6%), as shown in Table 2 . In 10 non-clear cell type RCC patients, 1 patient had a partial response (10%) and disease control was achieved in 8 patients. The median PFS was 5.1 months (95% CI, 4.2 6.0 months) and the median OS was 9.0 In addition, in the subgroup who had prior targeted agent treatment (7 patients), 6 patients reached stable disease with 1.5 months (95% CI 0.0 6.7 months) of the median PFS and 12.0 months (95% CI, 1.4 22.5 months) of the median OS. We also evaluated the difference between dosing schedule. The response rate was 25.8% and the disease control rate was 82.3% in the 50 mg 4 weeks on -2 weeks off dosing schedule, as compared with 35.7% and 92.9%, respectively, in the 37.5 mg daily treatment schedules ( Table 2 ). The median PFS in both the standard and other dosing schedules was 7.2 months.
Statistical analysis
Toxicity
A total 76% of the patients had a dose interruption or dose reduction due to adverse events, whereas only 11% of patients discontinued treatment due to toxicity. Stomatitis and diarrhea were the most commonly reported treatment-related adverse events (63.2% and 60.5%, respectively), but the rate of severe cases with grade 3 or more was not prevalent (10.5% and 6.6%, respectively), as shown in Table 3 . Adverse events which were reported with a 50% frequency were fatigue (57.9%), anorexia (59.2%) and handfoot syndrome (52.6%). A decrease in the left ventricular ejection fraction of grade 1 was reported in only 1 case, and was without clinical significance. Thyroid function tests were conducted in 45 patients. Eleven cases (24.4%) of hypothyroidism were noted, and 8 (17.8%) patients needed thyroid hormone replacement. In addition, we did not observev hemolytic uremic syndrome or thrombotic thrombocytopenia purpura in this group of patients (11) .
The most common laboratory abnormality was thrombocytopenia (77.6%), and 38.2% of the patients experienced grade 3 or 4 thrombocytopenia, which was no clinical significance (such as bleeding; Table 4 ). Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine amino- 
D i s c u s s i o n
RCC is one of the malignancies with a dismal prognosis because of the modest response to conventional chemotherapeutic agents and cytokine therapy. With the elucidation of the molecular pathogenesis of RCC, sunitinib, one of the molecular targeted agents was introduced for the treatment of metastatic RCC (8, 12) . Previous studies have confirmed the promising efficacy of sunitinib as a standard first-line treatment for metastatic clear cell RCC (8, 12) . However, these studies were mainly performed for patients in Western countries. Only one small study was reported for Asian patients with RCC who were treated with sunitinib (13), thereby the potential ethnic difference in the efficacy and toxicity of sunitinib have not been established. This retrospective study showed that homogeneous Asian patients with metastatic or recurrent RCC who received sunitinib had comparable survival outcome with patients in previous randomized studies.
For the treatment outcome, the median PFS and OS were 7.2 and 22.8 months, respectively. We also showed a 27.6% objective response rate and an 84.2% disease control rate in this analysis. Previous global trials have demonstrated 8.3 and 11 months of the median PFS and objective response rate of 34% and 31% (8, 12) . Even though it is difficult to compare this retrospective study with previous phase III randomized trials, we observed that metastatic RCC patients in our study also benefitted from sunitinib treatment. Interestingly, in our study, more patients with poor prognostic factors were included. In terms of MSKCC risk group, 88.3% of patients were in the intermediate or poor groups in this study. In addition, unlike the reported randomized studies, 50% of patients had an ECOG PS 1, and 8 (10.5%) patients with an ECOG PS 2 were also included. Therefore, considering the selection bias of randomized controlled trials which includes relatively better performance status, this finding may reflect more reliable results in real clinical practice with possible benefit from sunitinib treatment for metastatic RCC patients.
In terms of non-hematologic toxicity profiles, stomatitis was the most frequent adverse event in our study, which accounted for 63.2% of the cases; however grade 3 or 4 stomatitis accounted for 10.5% and was manageable. Meanwhile, more stomatitis and handfoot syndrome were noticed in our study compared to the global trials. For hand-foot syndrome, a much higher rate of all grades and grade 3/4 toxicities (52.6% of all grades, 9.2% of grade 3 or 4) were noted in contrast to the previous trials (15 20% of all grades; 1 7% of grade 3 or 4). Similarly, for stomatitis, a much higher toxicity (63.2% of all grades; 10.5% of grade 3/4) was noted than in previous trials (13 25 % of all grades; 1 5 % of grade 3 or 4).
Hematologic toxicity, especially for thrombocytopenia, was more remarkable in this study. All grades of thrombocytopenia were 77.6%, and it was similar with Western data (8, 12) . However, patients in the present study experienced a much higher rate of grade 3 or 4 thrombocytopenia (38.2% in YUHS data versus 8% in the randomized phase III trial, respectively). In addition, thrombocytopenia was the most common cause of dose reduction, delay, and discontinuation in our study. Other grade 3 or 4 hematologic toxicities such as neutropenia (28.9%), anemia (23.7%), and leukopenia (18.4%) were also more frequent than in Western analyses. This finding was consistent with Japanese study involving sunitinib treatment (13) . Whether this toxicity is directly related to host factors such as poor PS, or prior numbers of treatments remains uncertain. A disparity in the toxicity profiles between Eastern and Western countries has been in colon cancer patients who received capecitabine (14) (15) (16) . Compared to Caucasians, a higher incidence of hand-foot syndrome and a lower rate of diarrhea occurred in non-Caucasian patients treated with capecitabine, suggesting an ethnic difference between Western and Eastern patients. As shown in patients receiving capecitabine treatment, this finding may be caused by ethnic differences. Therefore, these descriptive results should be interpreted cautiously and further study with a larger sample size and pharmacokinetic tests are needed to clarify this finding.
The current single center retrospective analysis had several limitations. The patients in this retrospective study consisted of a heterogenous population. Thirteen percent of the patients had nonclear cell RCC, and 9% of all patients had already received targeted agents before sunitinib.
Nevertheless, this study represents one of the few studies in which sunitinib treatment was evaluated for efficacy and toxicity in Asian patients with RCC. Our results indicated that sunitinib treatment was effective and tolerable in Korean patients with metastatic RCC. Further studies with biochemical data would further clarify the clinical significance of theses findings.
C o n c l u s i o n
This study assessed sunitinib treatment for recurrent/metastatic Korean patients with RCC in terms of efficacy and toxicity. PFS, OS, and RR in Korean patients was compatible to Western patients, although some toxicities in Korean patients were more frequent and severe, but were manageable.
